Epjevy ()
Orphan
- Region
- 🇪🇺 EU
- Company
- CTI Life Sciences Limited
- Status
- Application withdrawn
- Therapeutic area
- Primary Myelofibrosis
- Designations
- Orphan
- Application
- EMEA/H/C/004793
- ATC
- L01XE
- Official record
- www.ema.europa.eu
Indication
Treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have thrombocytopenia (platelet counts ?100,000 /?L).
Regulatory milestones
No milestones recorded in the last year.
Follow Epjevy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.